GlassScriptPhysician profile
Milton F Stembridge
NPI 1538731690
$3,740.36
in general payments reported to CMS, 2019-2025
36 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $886 · 2023: $2,060 · 2024: $353 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $361.33 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $351.90 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $331.23 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.50 | 2022-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.08 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $242.83 | 2021-2023 | Breztri, Farxiga, Fasenra |
| Novartis Pharmaceuticals Corporation | $219.93 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.14 | 2021-2023 | |
| Abbvie INC. | $171.75 | 2022-2023 | |
| Lilly USA, LLC | $153.17 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $134.56 | 2021-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $91.78 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Neurocrine Biosciences, INC. | $91.53 | 2022-2023 | Ingrezza |
| Biogen, INC. | $78.70 | 2021 | |
| Sumitomo Pharma America, INC. | $66.45 | 2023 | Gemtesa |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Stembridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.